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Abstract  
Background: Prescriptions of off-label dosing non-vitamin K ant gonist oral anticoagulants 
(NOACs) are common for Asian patients with atrial fbrillation (AF).  
Objective: To investigate the associations between inappropriate dosing of NOACs and 
clinical outcomes.  
Methods: We used medical data from a multi-center healthcare system in Taiwan including 
2,068, 5,135, 2,589, 1,483, and 2,342 AF patients taking dabigatran, rivaroxaban, apixaban, 
edoxaban and warfarin, respectively. The risks of ischemic stroke/systemic embolism (IS/SE) 
and major bleeding of patients treated with under-dosing or over-dosing NOACs were 
compared to on-label dosing NOACs and warfarin. 
Results: Around 27% and 5% of AF patients were treated with under-dosing and over-dosing 
NOACs, respectively. Compared to on-label dosing, under-dosing NOACs were associated 
with a significantly higher risk of IS/SE (aHR 1.59, 95%CI 1.25-2.02; P<.001), while over-
dosing NOACs were associated with a significantly higher risk of major bleeding (aHR 2.01, 
95%CI 1.13-3.56; P=0.017). Compared to warfarin, the four on-label dosing NOACs were all 
associated with a comparable risk of IS/SE and a significantly lower risk of major bleeding, 
while under-dosing NOACs were associated with a higher risk of IS/SE (aHR 1.46; 
P=0.012). 
Conclusions: Around 3 in 10 Asian AF patients were treated with off-label dosing NOACs in 
daily practice. Compared to on-label dosing, underdosing was associated with a higher risk of 
IS/SE, while overdosing was associated with a higher risk of major bleeding. Even for Asian 
AF patients at a higher risk of bleeding, NOACs should still be prescribed at the dosing 
following clinical trial criteria and guideline recommendations. 
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Introduction 
Stroke prevention is central to the managements of patients with atrial fibrillation (AF), 
and long-term use of oral anticoagulants (OACs) effectively reduces the risk of stroke.1 The 
non-vitamin K antagonist oral anticoagulants (NOACs) provide an alternative option to the 
vitamin K antagonists (VKA, eg.warfarin) and are becoming the preferred choice for stroke 
prevention in guidelines.2,3  
Since routine monitoring of drug concentration is not necessary for NOACs, the 
selection of appropriate dose of NOACs according to the dosage criteria defined in 
randomized controlled trials (RCTs) is very important. Nevertheless, prescriptions of off-
label dosing NOACs remained as a major problem in the daily practice. In a previous report 
from the United States, around 9.4% of AF patients received off-label under-dosed NOACs, 
which was associated with a worse clinical outcome.4 Since the Asian population is 
associated with a higher bleeding risk such as intracranial hemorrhage (ICH),5 physicians 
generally tend to prescribe low-dose NOACs for Asian AF patients in daily clinical practice. 
In Taiwan, full-dosed dabigatran (150mg twice daily), rivaroxaban (20mg per day) and 
apixaban (5mg twice daily) were prescribed in only 12%, 6% and 38% of AF patients, 
respectively.6 Despite the high prescription rates of low-dosed NOACs, NOACs were still 
associated with a comparable or even lower risk of ischemic stroke/systemic embolism 
(IS/SE) compared to warfarin in some real-world data from Asian cohorts.7,8 These findings 
raise a question about whether there should be a lower dose of NOACs, so-called “Asian 
dose”, for Asian AF patients. Since information about renal function and body weight was 
usually not available in prior real-world studies, the actual percentages of these low-dose 
NOACs that were actually “off-label low-dose” and their associations with clinical outcomes 
remains unknown.  
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In the present study, we aimed to compare the clinical outcomes of AF patients treated 
with on-label or off-label dosing NOACs. We hypothesized that inappropriate dosing of 
NOACs without following individual labeling dosage r commendations may be associated 
with worse clinical outcomes in Asian AF patients.  
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Methods 
The study is based on data from the Chang Gung Research Database provided by Chang 
Gung Memorial Hospital. The interpretation and conclusions contained herein do not 
represent the position of Chang Gung Memorial Hospital (CGMH). We conducted the 
retrospective observational study by using the patients’ data from the CGMH Medical 
System. The CGMH Medical system composed of 3 major teaching hospitals and 4 tertiary 
care medical centers with a total of 10,050 beds an admits around 280,000 patients per year, 
and is the largest healthcare provider in Taiwan. In 2015, the emergent and outpatient 
department visits to CGMH Medical system were 500,0 and 8,500,000, respectively, 
approximately 1/10 of the Taiwanese medical service annually. The advantage of CGMH 
medical database is that each patient’s detailed chart record, diagnosis, laboratory, and 
imaging data are available. The personal information and identification number of each 
patient are encrypted and de-identified by using a consistent encrypting procedure; therefore, 
informed consent was waived for this study. Our study was approved by the Institutional 
Review Board of the Chang Gung Medical Foundation (201802075B0). 
Study cohort 
The flowchart of study design and patient enrollment is shown in Figure 1. The CGMH 
medical database was retrospectively searched for patients  20 years in whom new-onset 
AF was diagnosed from January 1st, 2010 to September 30st, 2018 (n = 53,852). There were 
15,841 patients treated with OACs after June 1st, 2012. Patients with a diagnosis of 
pulmonary embolism or deep venous thrombosis (n = 73), post valvular surgery (n = 215), 
mitral stenosis (n = 19), or end stage renal disease (n = 94) were excluded from the present 
study. Besides, patients whose information about body weight and serum creatinine were not 
available within 6 months before the dates when OACs were prescribed were also excluded 
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(n = 1,823). Finally, a total of 2,068, 5,135, 2,589, 1,483, and 2,342 AF patients treated with 
dabigatran, rivaroxaban, apixaban, edoxaban and warfarin, respectively, constituted the study 
population.  
Eligibility and dosage adjustment of NOACs 
In the present study, the definitions of eligibility and dosage adjustment criteria of four 
NOACs are summarized inTable 1. Patients treated with NOACs were defined as “off-label 
underdosing”, “on-label dosing”, and “off-label overdosing” generally based on the dosage 
reduction criteria of pivotal NOACs randomized trials nd recommendations of international 
society guidelines.9-14 Of note, there were no prospective dose-reduction criteria for patients 
treated with dabigatran in the RE-LY study.9 However, dabigatran 110 mg bid was suggested 
for patients aged > 80 years, age 75-80 years with a high risk of bleeding or concomitant use 
of verapamil based on the prior study and expert opini ns.14-16 For rivaroxaban, Taiwan Food 
and Drug Administration (FDA) approved either standrd-dose regimen (20mg/day for 
patients with a creatinine clearance rate [CCr] >50ml/min and 15mg/day for those with a 
CCr <50 ml/min), following the ROCKET AF dosage crite a, or low-dose regimen 
(15mg/day for patients with a CCr >50 ml/min and 10mg/day for those with a CCr <50 
ml/min), following the J-ROCKET AF dosage criteria, for stroke prevention in AF 
patients.10,11 Therefore, patients following either ROCKET-AF or J-ROCKET AF dosage 
criteria for rivaroxaban were defined as on-label dosing in the present study. In case of 
apixaban, if 2 of 3 criteria (age >80 years, body weight <60 kg, and measured serum 
creatinine >1.5 mg/dl) were met, the dosage of apixaban was reduced from 5 mg bid to 2.5 
mg bid.12 For patients with a CCr between 15-30 ml/min, apixban 2.5 mg bid was 
recommended.14 For edoxaban, if any of 3 criteria (body weight < 60 kg, CCr <50 ml/min, 
and concomitant use of P-glycoprotein inhibitor) was met, the daily dose of edoxaban was 
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reduced from 60mg to 30 mg.13 The off-label over-dosing was defined as the prescriptions of 
NOACs at the full dose even when patients met the dosage reduction criteria mentioned 
above. Conversely, the off-label under-dosing was defined as the prescriptions of NOACs at 
the reduced dose even when patients did not meet th dosage reduction criteria. Of note, 
prescriptions of dabigatran for patients with a CCr <30 ml/min or use of rivaroxaban, 
apixaban and edoxaban for patients with a CCr <15 ml/min were defined as overdosing in our 
study.14 
Study outcomes 
We reported the clinical outcomes of IS/SE and major bleeding for AF patients treated 
with NOACs. All study outcomes were defined on the basis of the first discharge diagnosis to 
avoid misclassification. The major bleeding events were defined as the total number of 
hospitalized events of ICH, gastrointestinal bleeding, and other sites of critical bleeding. The 
follow-up period was defined as the duration from the drug index date until the occurrence of 
study outcomes, mortality, or until the end date of the study period (September 30th, 2018), 
whichever came first. The risks of clinical events of underdosing and overdosing groups were 
compared to that of on-label dosing group. Besides, the risks of clinical events of NOACs in 
each dosing groups were compared to that of warfarin. 
Statistical analysis 
Data are presented as the mean value (standard deviation [SD]) for continuous variables 
and proportions for categorical variables. Differenc s between continuous values were 
assessed using the unpaired two-tailed t-test or one-way analysis of variance (ANOVA) when 
the comparisons of 3 groups were performed. Differences between nominal variables were 
compared by the chi-squared test. The rates of clinica  events were assessed using the Cox 
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regression analysis. The proportional hazards assumption was tested using Schoenfeld 
residual test which showed no non-proportionality. All statistical significances were set at a p
< 0.05. 
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Results 
The clinical characteristics of study population are shown in Table 2.  There were 7,764 
(68.9%), 2,999 (26.6%), and 512 (4.5%) patients treated with on-label dosing, off-label under 
dosing, and off-label over-dosing NOACs, respectively. Compared to on-label dosing group, 
patients receiving under-dosing NOACs were younger with a lower mean CHA2DS2-VASc 
and HAS-BLED scores, while patients receiving over-dosing NOACs were older and had 
higher CHA2DS2-VASc and HAS-BLED scores. The CCr was higher in under-dosing and 
lower in over-dosing groups compared to on-label dosing one. Baseline medications were not 
significantly different among three groups, except for a higher prescription rate of verapamil 
in the over-dosing group.    
The proportions of different dosing groups of 4 NOACs are shown in Figure 2. The 
highest rate of on-label dosing was observed for rivaroxaban (81%), followed by edoxaban 
(67%), apixaban (65%) and dabigatran (44%). For all NOACs, the percentages of 
underdosing (17%-48%) were higher than overdosing (2-10%). Supplemental Figure 1 
shows the percentages of patients receiving on-label dosing, under-dosing and over-dosing 
NOACs in different groups stratified by age, CHA2DS2-VASc and HAS-BLED scores. 
Generally, underdosing was more common among younger patients and those having a 
CHA2DS2-VASc score <4, whereas over-dosing NOACs, except for edoxaban, were more 
common for elderly patients. Baseline characteristics of patients treated with each NOACs 
are summarized in Supplemental Tables 1 to 4. 
Clinical outcomes of patients treated with off-label dosing vs. on-label dosing NOACs 
Overall, those 2,999 patients taking under-dosing NOACs were associated with a 
significantly higher risk of IS/SE (adjusted hazard ratio [aHR] 1.59, 95% confidence interval 
Downloaded for Anonymous User (n/a) at Aalborg Hospital from ClinicalKey.com by Elsevier on August 04, 2020.
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[CI] 1.25-2.02; P < .001) and a similar risk of major bleeding (aHR 0.80, 95% CI 0.50-1.27; 
P = 0.337) compared to 7,764 patients taking on-label dosing NOACs, after the adjustment 
for age, gender, CHA2DS2-VASc score, HAS-BLED score and CCr (Figure 3A). Of note, 
patients taking off-label under-dosing rivaroxaban (n = 858) and apixaban (n = 799) were 
associated with a significantly higher risk of IS/SE than those treated with on-label dosing 
rivaroxaban (n = 4,191) and apixaban (n = 1,677).  
In contrast, those 512 patients taking off-label over-dosing NOACS were associated 
with a significantly higher risk of major bleeding (aHR 2.01, 95% CI 1.13-3.56; P = 0.017) 
and a similar risk of IS/SE (aHR 1.24, 95% CI 0.74-2.07; P = 0.415) than patients taking on-
label dosing NOACs (Figure 3B). Over-dosing rivaroxaban (n = 86) was associated with a 
significantly higher risk of IS/SE (aHR 2.53, 95% CI 1.17-5.45; P = 0.018) and major 
bleeding (aHR 3.06, 95% CI 1.10-8.49; P = 0.032) compared to on-label dosing (n = 4,191).  
Among patients receiving on-label dosing rivaroxaban (n = 4,191), 1,354 and 2,837 of 
them followed the ROCKET-AF and J-ROCKET AF dosing criteria, respectively. Off-label 
dosing rivaroxaban was associated with a higher risk of IS/SE or major bleeding compared to 
ROCKEK-AF (Supplemental Figure 2A) or J-ROCKET AF (Supplemental Figure 2B) 
dosing regimen. These findings were generally consistent to the results of the main analysis 
which pooled ROCKET-AF and J-ROCKET AF dosing together as the on-label dosing 
group. 
Subgroup analysis 
Supplemental Figure 3 shows the comparisons of off-label underdosing and o -label 
dosing in different subgroups of patients. Consistent with the results of principal analysis, 
patients treated with off-label under-dosing NOACs were associated with a higher risk of 
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ISS/E but a comparable risk of major bleeding than those treated with on-label dosing across 
all subgroups (all Pint >0.05). Supplemental Figure 4 shows the comparisons of off-label 
overdosing and on-label dosing in different subgroups of patients. The increased risk of 
major bleeding for off-label over-dosing compared to on-label dosing was observed in 
different subgroups (all Pint >0.05). 
Different NOAC dosing groups compared to warfarin 
The clinical characteristics of patients taking NOACs and warfarin are shown in 
Supplemental Table 5. Those patients treated with NOACs (n = 11,275) were older, had 
more co-morbidities and higher mean CHA2DS2-VASc and HAS-BLED scores compared to 
the warfarin group (n = 2,342). Patients taking four on-label dosing NOACs were all 
associated with a comparable risk of IS/SE and a significantly lower risk of major bleeding 
compared to those receiving warfarin (Figure 4A). In contrast, patients treated with off-label 
under-dosing NOACs, especially for rivaroxaban (aHR 1.92, 95%CI 1.28-2.87; P = 0.002) 
and apixaban (aHR 1.71, 95%CI: 1.10-2.66; P = 0.017), were associated with a significantly 
higher risk of IS/SE than those treated with warfarin (Figure 4B). Patients treated with off-
label over-dosing NOACs were associated with a comparable risk of IS/SE (aHR 1.13, 
95%CI 0.66-1.93; P = 0.663) and major bleeding (aHR 1.07, 95%CI 0.60-1.90; P = 0.814) 
compared to those treated with warfarin (Figure 4C).  
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Discussion 
In the present study, we investigated the associatins between inappropriate dosing of 
four NOACs and clinical outcomes of Asian AF population in daily practice. Our principal 
findings are as follows: (i) around 27% and 5% of patients were treated with off-label under-
dosing and overdoing NOACs, respectively; (ii) compared to on-label dosing NOACs, off-
label under-dosing NOACs were associated with a significantly higher risk of IS/SE, whereas 
off-label overdosing NOACs were associated with a significantly higher risk of major 
bleeding; and (iii) compared to warfarin, all four on-label dosing NOACs were associated 
with a comparable risk of IS/SE and a lower risk of major bleeding, whereas underdoing was 
associated with a higher risk of IS/SE. These results highlighted the importance of 
prescriptions of NOACs at the on-label dosing even for Asians AF patients who were more 
prone to bleeding.  
Prevalence of off-label dosing NOACs  
Although there are various registry and administrative studies investigating the 
effectiveness and safety of NOACs for AF stroke prevention in real-world practice, a key and 
fundamental limitation is the inability to calculate CCr due to the absence of data about body 
weight and serum creatinine in most datasets, making it difficult to distinguish whether 
patients were actually treated with an appropriate dosing NOAC or not. Until now, there have 
been few clinical studies evaluating the impacts of inappropriate dosing of NOACs in AF 
patients.  
In the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial 
Fibrillation) study, around 13% of patients received NOACs at an inappropriate dosing 
(underdoing in 9.4% and overdosing in 3.4%) which were associated with an increased risk 
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of clinical events.4 Yao et al. studied 14,865 AF patients treated withapixaban, dabigatran, or 
rivaroxaban.17 Among the 1,473 patients with a renal indication fr dose reduction, 43% were 
overdosed, which was associated with a higher risk of major bleeding but no significant 
difference in risk of stroke. Among the 13,392 patien s with no renal indication for dose 
reduction, 13% were potentially underdosed. This underdosing was associated with a higher 
risk of stroke but no significant difference in risk of major bleeding in apixaban-treated 
patients. Compared to these 2 studies from the United States, the percentage (32%) of off-
label dosing, mainly due to underdosing (27%), was higher in our study including Chinese 
AF patients. This reflects how physicians tended to prescribe low-dosed NOACs, even 
against the standard labeling, for Asian AF patients probably due to the concern of the higher 
risk of bleeding for Asians and the lack of data regarding this issue.  
Off-label dosing NOACs and clinical outcomes  
Similar to previous studies of non-Asians,4,17 we showed that underdosing NOACs were 
associated with an 59% and 46% increased risk of IS/SE compared to on-label dosing 
NOACs and warfarin, respectively. Of note, the underdoing was not associated with a 
significantly lower risk of major bleeding compared to on-label dosing NOACs, the reason 
why they were often prescribed. The increased risk of IS/SE for underdoing NOACs was 
particularly evident for rivaroxaban and apixaban. Our data are consistent with the previous 
study by Yao et al. showing that under-dosed apixaban in patients without severe renal 
impairment was associated with a nearly 5-fold increased risk of stroke but without a 
reduction of major bleeding when compared to those taking on-label dosing apixaban.17 For 
rivaroxaban, the off-label underdosing (10mg/day for patients with a CCr >50 min/day) 
defined in our study was associated with a 2-fold increased risk of IS/SE compared to on-
label dosing and warfarin, and therefore, should be avoided.  
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Interestingly, we did not observe a higher risk of IS/SE for patients treated with 
underdoing dabigatran or edoxaban. Dabigatran 110 mg twice daily was the only low-dosed 
NOAC without any specified dosage criteria which was compared to warfarin in the 
randomized trial.9 Lee et al. analyzed 1,834 non-valvular AF patients treated with warfarin, 
dabigatran 150 mg, and dabigatran 110 mg,18 and the dabigatran 110 mg group was further 
classified as off-label or on-label dosing following European labeling.15 The results indicate 
that both on-label and off-label dabigatran 110 mg displayed a comparable efficacy and a 
lower risk of major bleeding compared to warfarin.18 Our results were consistent with above 
studies showing that even the guideline-discordant use of dabigatran 110 mg demonstrated a 
similar efficacy compared to on-label dosing dabigatran or warfarin. However, further 
prospective studies are necessary to evaluate the optimal dosage of dabigatran in Asian AF 
patients.  
In case of edoxaban, our results indicated that off-label under-dosing edoxaban was not 
associated with a significantly higher risk of IS/SE compared to on-label dosing edoxaban 
(aHR 1.43, 95% CI 0.53-3.89) or warfarin (aHR 1.53, 95% CI 0.64-3.65). However, our 
results should not be interpreted as off-label underdosing edoxaban could be prescribed for 
Asian AF patients since the non-significant increase in risk of IS/SE may be because of the 
relatively small sample size of edoxaban users in our study. Furthermore, even with on-label 
dosing edoxaban, the risk of major bleeding was not higher than off-label underdosing 
edoxaban and still significantly lower than warfarin (aHR 0.39, 95% CI 0.15-0.99). Therefore, 
off-label low-dosing edoxaban should generally not be considered for the Asian AF 
population.  
Limitations 
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There are several limitations of the present study. First, the present study is a 
retrospective study, and therefore, the results from the individual NOAC may be confounded 
by the bias of prescriptions (e.g., a perceived risk may result in conscious avoidance in use of 
specific NOAC in specific patient populations). Second, our study was performed in an 
intention to treat design, and did not take the changes of dosages of NOACs which may result 
in different categorizations of patients into considerations. Third, there was no universal and 
pre-specified algorithm for the measurements of body weight and serum creatinine due to the 
retrospective and observational study design. Althoug  we have excluded patients without 
information of body weight and serum creatinine within 6 months before the prescriptions of 
OACs, there was only 69% of patients whose data were measured within 3 months of NOAC 
prescriptions. Lastly, the Chang Gung Research Database we used in the present study were 
based on the closed CGMH Medical System without external link to protect each patient’s 
privacy. Therefore, data from other medical care systems outside CGMH were not available, 
and underestimations of medical activities for some patients were possible. However, CGMH 
database represented 1/10 of the whole Taiwanese medical service and included data about 
laboratory examinations. Its large sample size and vailable data of body weight and CCr 
enabled us to investigate the issue about off-label dosing NOACs.    
Conclusion  
Around 3 in 10 Asian AF patients were treated with off-label dosing NOACs in daily 
practice. Compared to on-label NOAC dosing, underdosing was associated with a higher risk 
of IS/SE without a lower risk of major bleeding while overdosing was associated with a 
higher risk of major bleeding without a lower risk of IS/SE. Even for Asian AF patients at a 
higher risk of bleeding, NOACs should still be prescribed at the dosing following clinical 
trial criteria and guideline recommendations. 
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Figure Legends 
Figure 1 A flowchart of patient enrollment. A total of 2,068, 5,135, 2,589, 1,483, and 
2,342 AF patients treated with dabigatran, rivaroxaban, apixaban, edoxaban and warfarin, 
respectively, have constituted the study population.  
AF = atrial fibrillation; NOACs = non-vitamin K antagonist oral anticoagulants; OACs = oral 
anticoagulants  
 
Figure 2 Proportions of different dosing groups of 4 NOACs. Overall, around 69%, 27% 
and 5% of patients were treated with on-label dosing, off-label under dosing, and off-label 
over-dosing NOACs, respectively. For all NOACs, thepercentages of underdosing (17%-
48%) were higher than overdosing (2-10%).  
NOACs = non-vitamin K antagonist oral anticoagulants 
 
Figure 3 Clinical outcomes of patients treated with off-label dosing vs. on-label dosing 
NOACs. Compared to on-label dosing, under-dosing NOACs were associated with a 
significantly higher risk of IS/SE and a similar risk of major bleeding (Figure 3A), while 
over-dosing NOACS were associated with a significantly higher risk of major bleeding and a 
similar risk of IS/SE (Figure 3B). 
*Adjustment for age, gender, CHA2DS2-VASc score, HAS-BLED score and CCr 
aHR = adjusted hazard ratio; CCr = creatinine clearance rate; CI = confidence interval; IS/SE 
= ischemic stroke/systemic embolism; NOACs = non-vitam n K antagonist oral anticoagulant 
 
Figure 4 Clinical outcomes of NOACs in different dosing groups compared to warfarin. 
Patients taking four on-label dosing NOACs were all associated with a comparable risk of 
IS/SE and a significantly lower risk of major bleeding compared to those receiving warfarin 
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(Figure 4A). In contrast, patients treated with off-label under- osing NOACs were associated 
with a significantly higher risk of IS/SE than those treated with warfarin (Figure 4B). 
Patients treated with off-label over-dosing NOACs were associated with a comparable risk of 
IS/SE and major bleeding compared to those treated with warfarin (Figure 4C). 
*Adjustment for age, gender, CHA2DS2-VASc score, HAS-BLED score and CCr 
Abbreviations were the same as Figure 3. 
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Table 1. Definitions of eligibility and dosage adjustments of NOACs 
 
 On-label dosing Off-label under-dosing Off-label over-dosing 
Dabigatran dabigatran 110 mg bid if any of three criteria was met: 
- age >80 years  
- age 75-80 years with a high risk of bleeding  
- concomitant use of verapamil 
                OR 
dabigatran 150 mg bid if none of the dosage reduction  
criteria was met 
dabigatran 110 mg bid for patients without 
 any dosage reduction criteria 
 
dabigatran 150 mg bid if any  
dosage reduction criteria was met 
             OR 
use of dabigatran if CCr <30 ml/min 
Rivaroxaban rivaroxaban 20 mg (ROCKET-AF) or 15 mg (J-ROCKET AF) 
             qd if CCr >50 ml/min 
                     OR  
rivaroxaban 15 mg (ROCKET-AF) or 10 mg (J-ROCKET AF) 
 qd if CCr <50 ml/min 
rivaroxaban 10 mg qd if CCr >50 ml/min rivaroxaban 20 mg qd if CCr <50 ml/min 
               OR 
use of rivaroxaban if CCr <15 ml/min 
Apixaban  apixaban 2.5 mg bid if > 2 of 3 criteria were met 
- aged >80 years  
- serum creatinine >1.5 mg/dl 
- body weight <60 kg 
                OR 
apixaban 2.5 mg bid if CCr between 15-30 ml/min 
                     OR 
apixaban 2.5 mg bid if the dosage  
reduction criteria were not met 
 
 
apixaban 5 mg bid for patients who met  
the dosage reduction criteria 
             OR 
use of apixaban if CCr <15 ml/min 
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apixaban 5 mg bid if the dosage reduction criteria were not met 
Edoxaban edoxaban 30 mg qd if any of three criteria was met: 
- body weight <60 kg 
- CCr <50 ml/min 
- use of P-glycoprotein inhibitor 
               OR 
edoxaban 60 mg qd if none of the dosage reduction cr teria  
was met 
edoxaban 30 mg qd for patients who did 
not meet the dosage reduction criteria 
            OR 
use of edoxaban 15 mg qd 
edoxaban 60 mg qd for patients who met  
the dosage reduction criteria 
             OR 
use of edoxaban if CCr <15 ml/min 
 
CCr = creatinine clearance rate 
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Table 2. Baseline characteristics of AF patients treated with NOACs 
 
  Overall 
(n = 11,275) 
On label 
dose 
(n = 7,764) 
Off-label  
under-dosing 
(n = 2,999)  
Off-label  
over-dosing 
(n = 512) 
P value 
(ANOVA) 
Baseline characteristics  
Age, yrs 74.21±10.40 74.87±10.63 71.70±9.41 78.90±9.23 <.001 
Female, n (%)  4684 (42%) 3281 (42%) 1132 (38%) 271 (53%) <.001 
Body weight, kg 65.44±14.23 64.81±14.32 68.45±13.32 57.37±13.72 <.001 
CHA2DS2-VASc score 3.49±1.60 3.57±1.61 3.21±1.54 3.89±1.51 <.001 
HAS-BLED score 2.77±1.23 2.80±1.22 2.67±1.23 2.93±1.19 <.001 
Past medical history, n (%)      
Chronic lung disease 3264 (29%) 2299 (30%) 802 (37%) 163 (32%) 0.004 
Chronic liver disease 2205 (20%) 1510 (19%) 606 (20%) 89 (17%) 0.301 
Congestive heart failure 1205 (11%) 882 (11%) 275 (9%) 48 (9%) 0.003 
Hypertension 8464 (75%) 5891 (76%) 2182 (73%) 391 (76%) 0.003 
Hyperlipidemia 4816 (43%) 3332 (43%) 1270 (42%) 214 (42%) 0.761 
Diabetes mellitus 3855 (34%) 2700 (35%) 981 (33%) 174 (34%) 0.128 
Previous stroke 1973 (17%) 1391 (18%) 493 (16%) 89 (17%) 0.195 
Ischemic heart disease   1345 (12%) 903 (12%) 381 (13%) 61 (12%) 0.305 
Gout 1797 (16%) 1284 (17%) 423 (14%) 90 (18%) 0.005 
Malignancy 1792 (16%) 1236 (16%) 458 (15%) 98 (19%) 0.086 
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Baseline laboratory data  
Hemoglobin, g/dl 12.95±2.15 12.88±2.15 13.25±2.07 12.31±2.30 <.001 
Platelet, x 1000/Ul 202.63±73.46 202.08±70.04 204.96±74.07 197.61±76.07 0.083 
Creatinine clearance, ml/min 60.89±29.12 58.75±29.64 69.73±25.87 41.65±23.17 <.001 
ALT, U/L  31.09±83.85 30.51±87.69 31.86±66.42 35.32±110.38 0.417 
Baseline medications, n (%)      
Use of NSAIDs 1543 (14%) 1043 (13%) 417 (14%) 83 (16%) 0.192 
Use of ACEI/ARB 6151 (55%) 4279 (55%) 1606 (54%) 266 (52%) 0.166 
Use of loop diuretics 3247 (29%) 2320 (30%) 767 (26%) 160 (31%) <.001 
Use of amiodarone 2399 (21%) 1609 (21%) 683 (23%) 107 (21%) 0.065 
Use of dronedarone 410 (4%) 270 (3%) 123 (4%) 17 (3%) 0.279 
Use of quinidine 0(0%) 8 (0%) 1 (0%) 1 (0%) 0.392 
Use of beta-blocker 6582 (58%) 4492 (58%) 1794 (60%) 296 (58%) 0.174 
Use of diltiazem 2145 (19%) 1484 (19%) 563 (19%) 98 (19%) 0.919 
Use of verapamil 494 (4%) 375 (5%) 68 (2%) 51 (10%) <.001 
Use of digoxin 1811 (16%) 1279 (16%) 457 (15%)* 75 (15%)*† 0.198 
Use of statin  3687 (33%) 2539 (33%) 993 (33%) 155 (33%) 0.449 
 
ACEI = angiotensin-converting-enzyme inhibitor; AF = atrial fibrillation; ALT = alanine aminotransferase; ARB = angiotensin II receptor 
antagonists; CHA2DS2-VASc = congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic 
attack, vascular disease, age 65 to 74 years, female; HAS-BLED = hypertension, abnormal renal or liver function, stroke, bleeding history, labile 
INR, age 65 years or older, and antiplatelet drug or alcohol use; NOAC = non-vitamin K antagonist oral anticoagulant; NSAIDs = non-steroidal 
D
ow
nloaded for A
nonym
ous U
ser (n/a) at A
alborg H
ospital from
 C
linicalK
ey.com
 by E
lsevier on A
ugust 04, 2020.
For personal use only. N
o other uses w
ithout perm
ission. C
opyright ©
2020. E
lsevier Inc. A
ll rights reserved.
anti-inflammatory drugs 
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AF patients 
treated with OACs
after 2012/06/01  
(n = 15,841) 
NOACs 
(n = 11,275)
Dabigatran (n = 2,068)  
Rivaroxaban (n = 5,135)
Apixaban (n = 2,589)
Edoxaban (n = 1,483)
Warfarin 
(n = 2,342)
Patients with newly-diagnosed AF
from 2010/01/01-2018/09/30
(n = 53,852)
Exclusion if
no baseline data of 
body weight and 
serum creatinine
(n = 1,823)
Exclusion if no OACs were 
prescribed after 2012/06/01
(n = 38,011)
Exclusion if diagnosis of 
pulmonary embolism or deep 
vein thrombosis (n = 73)
Exclusion if valvular surgery 
(n = 215)
Exclusion if diagnosis of 
mitral stenosis (n = 19)
Exclusion if diagnosis of 
end stage renal disease (n = 94)
Non-valvular AF patients 
treated with OACs
after 2012/06/01  
(n = 15,440) 
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Off-label over-dosing   
512 (5%)
On-label dosing   
7,764 (69%)
All NOACs
11,275
Over-dosing  
163 (8%)
On-label dosing   
901 (44%)
Over-dosing   
86 (2%)
On-label dosing   
4,191 (81%)
Dabigatran          Rivaroxaban              Apixaban Edoxaban
2,068                       5,135                       2,589                       1,483          
Over-dosing   
113 (4%)
On-label dosing   
1,677 (65%)
Under-dosing   
799 (31%)
Over-dosing   
150 (10%)
Under-dosing   
338 (23%)
On-label dosing   
995 (67%)
Off-label under-dosing 
2,999 (27%)
Under-dosing
1,004 (48%)
Under-dosing   
858 (17%)
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